Crestline Management’s Pfizer PFE Stock Holding History

Crestline Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-18,709	Closed	-$607K	–	163
2017 Q1	$607K	Buy	+18,709	New	+$590K	0.11%	81

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Crestline Management's PFE Position: Q2 2017 in Review

Crestline Management sold out of Pfizer (PFE) in Q2 2017, closing a stake of 18,709 shares — an estimated $607K sold.

Crestline Management first reported a position in PFE in Q1 2017 and held it in 1 quarter. The position peaked at $607K in Q1 2017. 2,050 funds tracked by Wall St. Rank hold PFE as of Q2 2017.

Crestline Management reported no remaining Pfizer position as of Q2 2017 after selling out during the quarter.
Crestline Management sold 18,709 Pfizer shares in Q2 2017, an estimated $607K.
Crestline Management first reported a position in Pfizer in Q1 2017 and held it in 1 quarter.
Crestline Management's Pfizer position peaked at $607K in Q1 2017.
2,050 funds tracked by Wall St. Rank held Pfizer as of Q2 2017.

Based on Crestline Management's 13F filing for Q2 2017, filed 14 Aug 2017.